DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
DexCom
DXCM
Hutchmed (China)
HCM
New Fortress Energy
NFE
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
DNTH Dianthus Therapeutics
- 24.490
- +0.360+1.49%
Close Feb 14 16:00 ET
- 24.490
- 0.0000.00%
Post 16:00 ET
724.83MMarket Cap-10.72P/E (TTM)
25.455High23.610Low332.87KVolume24.500Open24.130Pre Close8.13MTurnover2.75%Turnover RatioLossP/E (Static)29.60MShares33.77052wk High2.15P/B296.53MFloat Cap18.34552wk Low--Dividend TTM12.11MShs Float336.000Historical High--Div YieldTTM7.65%Amplitude5.136Historical Low24.438Avg Price1Lot Size
About Dianthus Therapeutics Company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Company Profile
SymbolDNTH
Company NameDianthus Therapeutics
Listing DateJun 21, 2018
Founded2015
CEOMr. Marino Garcia
MarketNASDAQ
Employees53
Fiscal Year Ends12-31
Address7 Times Square,43rd Floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-929-999-4055
Websitehttp://dianthustx.com
Company Executives
- Name
- Position
- Salary
- Marino Garcia
- President, Chief Executive Officer and Director
- --
- Ryan Savitz
- Chief Financial Officer, Chief Business Officer and Treasurer
- --
- Edward G. Carr
- Chief Accounting Officer
- --
- Dr. Simrat Randhawa, M.D.
- Chief Medical Officer
- --
- Adam M. Veness
- Senior Vice President, General Counsel and Secretary
- --
- Leon O. Moulder, Jr
- Chairman of the Board
- --
- Dr. Jonathan Violin, M.B.A.,PhD
- Director
- --
- Dr. Steven Joseph Romano, M.D.
- Director
- --
- Anne M. McGeorge
- Independent Director
- --
- Alison F. Lawton
- Independent Director
- --
- Tomas Kiselak
- Independent Director
- --
- Paula Soteropoulos
- Independent Director
- --